SWOG S1607

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin



A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy


Limited institution study: open only to Billings Clinic

Cohort A (patients with at least one measurable visceral lesion) is temporarily suspended effective July 16, 2020.

Cohort B permanently closed to accrual effective June 1, 2020.